… In the second-line setting, numerous phase II trials of one or … phase III data exists in a large
number of patients with prior platinum therapy. In the first of two randomized phase III trials, …

… We conducted a global, randomized, placebo-controlled, phase II study in patients with
recurrent NSCLC evaluating onartuzumab plus erlotinib versus placebo plus erlotinib. …

… (39 patients in stage 1 of the study and an additional 21 patients in stage 2) were … two
confirmed objective responses were needed in stage 1 to allow expansion of the trial to stage 2…

… phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment
of patients with advanced non-small-cell lung cancer … with unresectable stage III and IV …

… A phase II trial was conducted to evaluate talabostat in combination with … phase II trial
reported that talabostat failed to induce an objective response in metastatic colorectal carcinoma …

… , we launched a single-arm prospective phase II trial to investigate whether it would be
possible to obtain a significant 2- and 3-year survival in these patients when treated radically. …

… Recently, Langer et al 17 confirmed our results in a phase II study of 28 patients who …
In conclusion, we believe that the reported phase II experiences, together with our own trial, …

… The results from this phase 2 trial showed substantial antitumour activity of dabrafenib plus
trametinib therapy in patients with treatment-naive BRAF V600E -mutant metastatic NSCLC. …

Purpose To determine the efficacy of cetuximab in patients with recurrent or progressive non–small-cell
lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. …

… This randomized phase II study evaluated the outcome of erlotinib with and without the …
with stage IIIB/IV non–small-cell lung cancer, no prior EGFR-TKIs, and performance status ≤ 2 …